# Audience Intelligence: GLP-1 pharmacy index

Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed. is the first audience because the report already names a repeated pain, reachable channels, and a validation test that can be run before software is complete.

## Segments
- **Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.**: Even after the FDA declared the GLP-1 shortages resolved (tirzepatide Dec 2024, semaglutide Feb 2025), patients still hit localized stockouts of specific doses and face cash prices that swing from roughly $199 to $1,000+ per month depending on whether they buy via LillyDirect, NovoCare, Costco, Walmart, or a retail pharmacy. There is no neutral, normalized, machine-readable index that tracks dose-level availability and the cheapest legitimate price for a given drug, dose, and ZIP at a point in time. Trigger: FDA removed tirzepatide (Mounjaro/Zepbound) from its shortage list in December 2024 and semaglutide (Ozempic/Wegovy) in February 2025, with phased 503A/503B compounding cutoff deadlines in early-to-mid 2025 — shifting the problem from blanket shortage to localized, dose-level stockouts. Budget signal: Free consumer finder for top-of-funnel and crowdsourced data; revenue from a B2B availability/price API and dashboard licensed to telehealth prescribers, employers/benefits brokers, and PBMs, plus possible referral fees to legitimate pharmacy or manufacturer-direct channels (no clinical affiliate of the drug itself).
- **Budget owner who feels the operational cost of the broken workflow.**: Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service. Trigger: AI-assisted product work and managed infrastructure reduce the first-version cost. Budget signal: $49-$499/month
- **Hands-on operator willing to pilot a narrow tool before a full rollout.**: Regulatory and liability exposure: showing or routing to GLP-1 sources touches HIPAA, state pharmacy law, drug-advertising rules, and the post-shortage crackdown on compounded GLP-1s — surfacing illegitimate or compounded sources could create legal risk. Trigger: Free consumer finder for top-of-funnel and crowdsourced data; revenue from a B2B availability/price API and dashboard licensed to telehealth prescribers, employers/benefits brokers, and PBMs, plus possible referral fees to legitimate pharmacy or manufacturer-direct channels (no clinical affiliate of the drug itself). Budget signal: $99-$1,000/year add-on
- **Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed. who still run the workflow in spreadsheets, generic docs, email, or chat threads.**: Even after the FDA declared the GLP-1 shortages resolved (tirzepatide Dec 2024, semaglutide Feb 2025), patients still hit localized stockouts of specific doses and face cash prices that swing from roughly $199 to $1,000+ per month depending on whether they buy via LillyDirect, NovoCare, Costco, Walmart, or a retail pharmacy. There is no neutral, normalized, machine-readable index that tracks dose-level availability and the cheapest legitimate price for a given drug, dose, and ZIP at a point in time. Trigger: The wedge is specific enough to test without claiming the whole market. Budget signal: Custom

## Channels
- **Reddit / forums**: Look for complaints, workarounds, and repeated questions. First move: Post a problem teardown for US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels. and ask how people solve it today.
- **Launch communities**: Launch traction shows whether the promise is legible. First move: Ship a narrow demo and watch which promise gets clicks.
- **Review and alternative pages**: Pricing and alternatives expose buyer objections. First move: Write an alternatives page that owns one narrow use case.
- **Community pain posts**: Use communities and forums where Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed. already describe the painful workflow. First move: Problem teardown, interview ask, and short demo clip
- **Direct outreach**: Direct conversations are the fastest way to verify budget ownership and switching cost. First move: Concierge pilot offer with a manually prepared sample

## Intent Keywords
`pharmacy workflow`, `index validation`, `pharmacy ai`, `index automation`, `healthtech`, `glp-1`, `pharmacy-data`, `price-transparency`, `b2b-data`, `telehealth`, `US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels.`

## Messaging Angles
- GLP-1 pharmacy index should be tested as a narrow first-win workflow for Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed..
- Replace a narrow workflow that reaches value without configuration-heavy onboarding. with a focused first-win workflow.
- Promise proof around problem resonance: 5+ calls or 10+ detailed replies..
- De-risk adoption with concierge review or paid template.

## Objections
- Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service.
- Regulatory and liability exposure: showing or routing to GLP-1 sources touches HIPAA, state pharmacy law, drug-advertising rules, and the post-shortage crackdown on compounded GLP-1s — surfacing illegitimate or compounded sources could create legal risk.
- Incumbents already occupy the niche: Ro (a well-funded telehealth company) offers a free supply tracker as a funnel, and Medfinder offers a paid concierge stock-finding service, so a standalone index must out-execute on data freshness and the B2B feed.
- Demand is shortage-driven and could soften further as supply fully normalizes and GLP-1 pills arrive, compressing the consumer pain point and the window for the data business.
- Needs real buyer access, not only desk research.
- Needs proof of budget or repeated urgency.